Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring

BMC Cancer

Ajai Chari²  Daher Hajje¹ 

[1] New York University School of Medicine, 500 1st Avenue, New York, NY, USA

[2] Mt Sinai School of Medicine, 1 Gustave Levy Place, Box 1185, New York, NY, USA

关键词: Multiple myeloma;    Vascular toxicity;    Cardiac toxicity;    Proteasome inhibitor;    Carfilzomib;   

Others  :  1117948
DOI  :  10.1186/1471-2407-14-915

 received in 2014-07-07, accepted in 2014-11-17,  发布年份 2014

【 摘 要 】

Background

Carfilzomib is a selective proteasome inhibitor approved in the United States in 2012 for the treatment of relapsed and refractory multiple myeloma. Although cardiopulmonary and vascular events have been reported infrequently, they can be potentially serious complications, and their incidence and pathophysiology following carfilzomib treatment remain poorly characterized in a real-world patient population.

Methods

We retrospectively reviewed the records of 67 patients with relapsed and/or refractory multiple myeloma treated at our institution.

Results

We describe 12 patients who experienced cardiac or vascular-related adverse events subsequent to carfilzomib-based treatment (median age, 59 years [range, 49–77]). Nine patients had prior autologous stem cell transplant, and three had prior anthracycline exposure. Detailed case reports are provided for five representative patients: (1) systemic hypertension in a 65-year-old Caucasian female with a history of hypertension, hypothyroidism, and stage III chronic kidney disease; (2) pulmonary hypertension in a 72-year-old Caucasian male with a history of recurrent respiratory infections and chronic right lower extremity deep venous thrombosis; (3) acute renal insufficiency with increased blood pressure in a 50-year-old Caucasian male with a history of hypertension and stage IV chronic kidney disease; (4) heart failure in a 64-year-old African American female with a history of hypertension; and (5) dyspnea and lung disease in a 58-year-old Asian American male with a history significant for hepatitis B virus infection.

Conclusions

While cardiac and vascular-related adverse events were reported in patients with relapsed and/or refractory multiple myeloma who were treated with carfilzomib, most patients had a history of the specific cardiac or vascular adverse event they exhibited and demonstrated an improvement or resolution in symptoms after the discontinuation of therapy. Appropriate screening and monitoring could potentially allow at-risk patients to benefit fully from treatment with carfilzomib.

【 授权许可】

   
2014 Chari and Hajje; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, Kapoor P, Dingli D, Hayman SR, Leung N, Lust J, McCurdy A, Russell SJ, Zeldenrust SR, Kyle RA, Rajkumar SV: Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2014, 28(5):1122-1129.
• [2]Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Kunkel L, Wear S, Wong AF, Orlowski RZ, Jagannath S: A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 2012, 120(14):2817-2825.
• [3]Onyx Pharmaceuticals, Inc: Kyprolis (carfilzomib) package insert. http://www.kyprolis.com/prescribing-information webcite
• [4]Siegel D, Martin T, Nooka A, Harvey RD, Vij R, Niesvizky R, Badros AZ, Jagannath S, McCulloch L, Rajangam K, Lonial S: Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica 2013, 98(11):1753-1761.
• [5]Elofsson M, Splittgerber U, Myung J, Mohan R, Crews CM: Towards subunit-specific proteasome inhibitors: synthesis and evaluation of peptide α′, β′-epoxyketones. Chem Biol 1999, 6(11):811-822.
• [6]Groettrup M, van den Broek M, Schwarz K, Macagno A, Khan S, de Giuli R, Schmidtke G: Structural plasticity of the proteasome and its function in antigen processing. Crit Rev Immunol 2001, 21(4):339-358.
• [7]Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho MN, Jiang J, Laidig GJ, Lewis ER, Parlati F, Shenk KD, Smyth MS, Sun CM, Vallone MK, Woo TM, Molineaux CJ, Bennett MK: Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 2007, 67(3):6383-6391.
• [8]O'Connor OA, Stewart AK, Vallone M, Molineaux CJ, Kunkel LA, Gerecitano JF, Orlowski RZ: A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin Cancer Res 2009, 15(22):7085-7091.
• [9]Wang Z, Yang J, Kirk C, Fang Y, Alsina M, Badros A, Papadopoulos K, Wong A, Woo T, Bomba D, Li J, Infante JR: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib. Drug Metab Dispos 2013, 41(1):230-237.
• [10]Badros AZ, Vij R, Martin T, Zonder JA, Kunkel L, Wang Z, Lee S, Wong AF, Niesvizky R: Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety. Leukemia 2013, 27(8):1707-1714.
• [11]Alsina M, Trudel S, Firman RR, Rosen PJ, O’Connor OA, Comenzo RL, Wong A, Kunkel LA, Molineaux CJ, Goy A: A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma. Clin Cancer Res 2012, 18(17):4830-4840.
• [12]Jagannath S, Vij R, Stewart AK, Trudel S, Jakubowiak AJ, Reiman T, Somlo G, Bahlis N, Lonial S, Kunkel LA, Wong A, Orlowski RZ, Siegel DS: An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk 2012, 12(5):310-318.
• [13]Vij R, Wang M, Kaufman JL, Lonial S, Jakubowiak AJ, Stewart AK, Kukreti V, Jagannath S, McDonagh KT, Alsina M, Bahlis NJ, Reu FJ, Gabrail NY, Belch A, Matous JV, Lee P, Rosen P, Sebag M, Vesole DH, Kunkel LA, Wear SM, Wong AF, Orlowski RZ, Siegel DS: An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood 2012, 119(24):5661-5670.
• [14]Yang J, Wang Z, Fang Y, Jiang J, Zhao F, Wong H, Bennett MK, Molineaux CJ, Kirk CJ: Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats. Drug Metab Dispos 2011, 39(10):1873-1882.
• [15]Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, Rekhtman G, Masliak Z, Robak T, Shubina A, Arnulf B, Kropff M, Cavet J, Esseltine DL, Feng H, Girgis S, van de Velde H, Deraedt W, Harousseau JL: Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 2011, 12(5):431-440.
• [16]Papadopoulos KP, Siegel DS, Vesole DH, Lee P, Rosen ST, Zojwalla N, Holahan JR, Lee S, Wang Z, Badros A: Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma. J Clin Oncol 2014. doi:10.1200/JCO.2013.52.3522
• [17]Lendvai N, Landau H, Lesokhin A, Tsakos I, Koehne G, Chung D, Devlin S, Hassoun H, Giralt SA: Phase II study of infusional carfilzomib in patients with relapsed or refractory multiple myeloma. Blood 2012, 120(Suppl 21):947. abstr
• [18]Armenian SH, Sun CL, Vase T, Ness KK, Blum E, Francisco L, Venkataraman K, Samoa R, Wong FL, Forman SJ, Bhatia S: Cardiovascular risk factors in hematopoietic cell transplantation survivors: role in development of subsequent cardiovascular disease. Blood 2012, 120(23):4505-4512.
• [19]Kistler KD, Rajangam K, Faich G, Lanes S: Cardiac event rates in patients with newly diagnosed and relapsed multiple myeloma in US clinical practice. Blood 2012, 120(Supp 21):2916. abstr
• [20]Atrash S, Tullos A, Panozzo S, Waheed S, Van Rhee F, Restrepo A, Muzaffar J, Bakhous A, Grazziutti M, Shahid Z, Apewokin S, Abdallah AOA, Barlogie B, Usmani SZ: Retrospective analysis of cardiovascular (CV) events following compassionate use of carfilzomib (CFZ) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM). J Clin Oncol 2013, 31(15s):8595. abstr
• [21]Kortuem KM, Stewart AK: Carfilzomib. Blood 2013, 121(6):893-897.
• [22]Furchgott RF, Zawadzki J: The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980, 288(5789):373-376.
• [23]Endemann DH, Schiffrin E: Endothelial dysfunction. J Am Soc Nephrol 2004, 15(8):1983-1992.
• [24]Fogli S, Nieri P, Breschi MC: The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage. FASEB J 2004, 18(6):664-675.
• [25]Stangl K, Stangl V: The ubiquitin-proteasome pathway and endothelial (dys)function. Cardiovasc Res 2010, 85(2):281-290.
• [26]Bender AT, Demady DR, Osawa Y: Ubiquitination of neuronal nitric-oxide synthase in vitro and in vivo. J Biol Chem 2000, 275(23):17407-17411.
• [27]Ito H, Kamei K, Iwamoto I, Inaguma Y, Garcia-Mata R, Sztul E, Kato K: Inhibition of proteasomes induces accumulation, phosphorylation, and recruitment of HSP27 and αB-crystallin to aggresomes. J Biochem 2002, 131(4):593-603.
• [28]Wei Q, Xia Y: Proteasome inhibition down-regulates endothelial nitric-oxide synthase phosphorylation and function. J Biol Chem 2006, 281(31):21652-21659.
• [29]Meiners S, Ludwig A, Stangl V, Stangl K: Proteasome inhibitors: poisons and remedies. Med Res Rev 2008, 28(2):309-327.
• [30]Meiners S, Ludwig A, Lorenz M, Dreger H, Baumann G, Stangl V, Stangl K: Nontoxic proteasome inhibition activates a protective antioxidant defense response in endothelial cells. Free Radic Biol Med 2006, 40(12):2232-2241.
• [31]Stangl V, Lorenz M, Meiners S, Ludwig A, Bartsch C, Moobed M, Vietzke A, Kinkel HT, Baumann G, Stangl K: Long-term up-regulation of eNOS and improvement of endothelial function by inhibition of the ubiquitin–proteasome pathway. FASEB J 2004, 18(2):272-279.
• [32]Herrmann J, Saguner AM, Versari D, Peterson TE, Chade A, Olson M, Lerman LO, Lerman A: Chronic proteasome inhibition contributes to coronary atherosclerosis. Circ Res 2007, 101(9):865-874.
• [33]Herrmann J, Wohlert C, Saguner AM, Flores A, Nesbitt LL, Chade A, Lerman LO, Lerman A: Primary proteasome inhibition results in cardiac dysfunction. Eur J Heart Fail 2013, 15(6):614-623.
• [34]Gupta A, Pandey A, Sethi S: Bortezomib-induced congestive cardiac failure in a patient with multiple myeloma. Cardiovasc Toxicol 2012, 12(2):184-187.
• [35]Honton B, Despas F, Dumonteil N, Rouvellat C, Roussel M, Carrie D, Galinier M, Montastruc JL, Pathak A: Bortezomib and heart failure: case-report and review of the French Pharmacovigilance database. Fundam Clin Pharmacol 2014, 28(3):349-352.
• [36]Voortman J, Giaccone G: Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report. BMC Cancer 2006, 6:129. BioMed Central Full Text
• [37]Enrico O, Gabriele B, Nadia C, Sara G, Daniele V, Giulia C, Antonio S, Mario P: Unexpected cardiotoxicity in haematological bortezomib treated patients. Br J Haematol 2007, 138(3):396-397.
• [38]Takamatsu H, Yamashita T, Kotani T, Sawazaki A, Okumura H, Nakao S: Ischemic heart disease associated with bortezomib treatment combined with dexamethasone in a patient with multiple myeloma. Int J Hematol 2010, 91(5):903-906.
• [39]Dasanu CA: Complete heart block secondary to bortezomib use in multiple myeloma. J Oncol Pharm Pract 2011, 17(3):282-284.
• [40]Li YF, Wang X: The role of the proteasome in heart disease. Biochim Biophys Acta 2011, 1809(2):141-149.
• [41]Tang M, Li J, Huang W, Su H, Liang Q, Tian Z, Horak KM, Molkentin D, Wang X: Proteasome functional insufficiency activates the calcineurin-NFAT pathway in cardiomyocytes and promotes maladaptive remodelling of stressed mouse hearts. Cardiovasc Res 2010, 88(3):424-433.
• [42]Korde N, Zingone A, Kwok ML, Manasanch EE, Bhutani M, Tageja N, Kazandjian D, Mailankody S, Costello R, Zhang Y, Burton D, Carter G, Wu P, Mulquin M, Zuchlinski D, Maric I, Calvo KR, Braylan RC, Roschewski M, Yuan C, Stetler-Stevenson M, Arthur DC, Lindenberg L, Kurdziel K, Choyke P, Steinberg SM, Landgren O: Phase 2 clinical and correlative study of carfilzomib, lenalidomide, and dexamethasone followed by lenalidomide extended dosing (CRD-R) in newly diagnosed multiple myeloma (MM) patients. Haematologica 2013, 98(Suppl 1):P228. abstr
• [43]Landgren O, Manasanch EE, Kwok M, Flanders A, Zingone A, Costello R, Mulquin M, Zuchlinski D, Carter G, Maric I, Calvo K, Braylan R, Tembhare P, Yuan C, Stetler-Stevenson M, Arthur DC, Lindenberg L, Choyke P, Kurdziel K, Steinberg S, Roschewski M, Korde N: Clinical and correlative (phase II) pilot study – carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (Dex) in high risk smoldering multiple myeloma (“early myeloma”). Clin Lymphoma Myeloma Leuk 2013, 13(Suppl 1):O-6. abstr